Advertisement


Related Videos

Lymphoma

Bertrand Coiffier, MD, PhD, on Radiotherapy Plus R-CHOP in Localized Diffuse Large B-Cell Lymphoma

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393, “R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group,” presented by Thierry Lamy, MD, PhD.

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Hematologic Malignancies

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Myelodysplastic Syndromes

Alan F. List, MD, on the CC-5013-MDS-005 Study

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 409, “Efficacy and Safety of Lenalidomide vs Placebo in RBC Transfusion–Dependent Patients With IPSS Low-/Intermediate-Risk Myelodysplastic Syndromes Without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents: Results From a Randomized Phase III Study (CC-5013-MDS-005),” presented by Valeria Santini, MD.

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following  Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.

Advertisement

Advertisement




Advertisement